[Version 8.1, 01/2017]

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

MIPREPOL, oily suspension for dogs and cats (IT)
SUROLAN, oily suspension for dogs and cats (ES, PT)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substances:
20 mg Miconazole (as nitrate)
4.48 mg Prednisolone (as acetate)
0.5293 mg Polymyxin B sulfate

Excipients:
For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Oily suspension for topical use

4. CLINICAL PARTICULARS

4.1 Target species
Dogs and cats

4.2 Indications for use, specifying the target species
Cats and dogs: topical treatment of otitis externa and skin infections caused by the following susceptible species:

Fungi and yeasts
Microsporum spp
Trichophyton spp.
Candida spp.
Malassezia pachydermatis
Gram-positive bacteria
Staphylococcus spp.
Streptococcus spp.
Gram-negative bacteria
Pseudomonas spp.
Escherichia coli

In the case of external otitis due to ear mites (*Otodectes cynotis*), the effect of this product is due to a physical action of its excipient and not to the intrinsic activity of the active substances. Its use in this indication has to be chosen only when there is a secondary infection caused by susceptible organisms.

The product also has anti-inflammatory and anti-pruritic activity.

4.3 Contraindications
Do not use in animals with perforated ear drums since Polymixin B is known to be a potential ototoxic agent.
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

4.4 Special warnings for each target species
Otitis is often secondary to primary causes which should be determined by an accurate diagnosis.

4.5 Special precautions for use

This veterinary medicinal product does not contain any antimicrobial preservative.

Special precautions for use in animals

For external use only.

Whenever possible, the veterinary medicinal product should only be used based on susceptibility testing.

Official, national and local antimicrobial policies should be taken into account when the product is used.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of resistant bacteria, fungi or yeasts to polimixin B or miconazol respectively.

Before the product is applied, the external auditory canal must be examined to ensure that the eardrum is not perforated in order to avoid the risk of transmission of the infection to the middle ear and to prevent damage to the cochlear and vestibular apparatus.

After recovery, ears should be checked at regular intervals for signs of reinfection.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental contact with eyes, seek medical advice immediately and show the package leaflet or the label to the physician.

People with known hypersensitivity to the active substances should avoid contact with the veterinary medicinal product.

Personal protective equipment consisting of single use disposable gloves should be worn when handling the veterinary medicinal product.

The veterinary medicinal product should not be administered by pregnant women.

4.6 Adverse reactions (frequency and seriousness)

In very rare cases hypersensitivity or allergic reactions to any of the active substances or excipients may occur.

Long-term use of topical corticosteroids may cause very rare local or systemic effect, including skin thinning and delay wound healing. Their immunosuppressant actions may weaken resistance to or exacerbate existing infections.

In very rare occasions the use of this product may be associated with deafness, mainly in elderly dogs. If this occurs, treatment should be stopped. Decreased hearing or deafness was reversible in the majority of cases.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

Can be used during pregnancy and lactation.

4.8 Interaction with other medicinal products and other forms of interaction

None known.

4.9 Amounts to be administered and administration route

For topical administration. Shake the bottle well before use.

At the beginning of treatment, hair surrounding or covering the lesions must be clipped; this should be repeated during treatment if necessary.

Ears:

Clean the auditory canal and place 3-5 drops of the product into the ear twice daily.

Massage the ear and the auditory canal gently but thoroughly to ensure proper distribution.
For infections caused *by Otodectes cynotis*, instill five drops twice daily for 14 days.

Skin: Having ensured the area to be treated is clean, apply a few drops of the product (depending on lesion size) twice a day. Wear single use disposable gloves and rub well.

Treatment should be continued until a few days after complete disappearance of the clinical symptoms. In some obstinate cases, treatment may be required for 2 to 3 weeks.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
No data available. Do not exceed the recommended dosage.

4.11 Withdrawal period(s)
Not applicable.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Otologicals, Corticosteriods and antiinfectives in combination.
ATCvet code: QS02CA01

5.1 Pharmacodynamic properties
This product is a combination of three active substances: one antifungal, one antibiotic and one corticosteroid.

Miconazole nitrate is a synthetic imidazole derivative with a pronounced antifungal activity: it selectively inhibits the biosynthesis of ergosterol, damaging the fungal cell wall membrane and altering its permeability and causing the loss of the intracellular organelles and the inhibition of glucose use.
Miconazole is active against dermatophytes and yeasts and have a certain bactericidal activity against some Gram positive bacteria, i.e. *Staphylococcus* spp and *Streptococcus* spp.

Polymyxin B is a polypeptide antibiotic with bactericidal activity. It binds to phospholipids in the cytoplasmic membrane, altering the membrane permeability. This results in lysis of the bacteria. Polymyxin B is mainly active against Gram negative bacteria, including *Pseudomonas* spp. Resistance to polymyxin B is not frequent, but there is complete cross-resistance with colistin.

Prednisolone is a synthetic glucocorticoid related to cortisol with anti-inflammatory, anti-itch and antiallergenic activities. The anti-inflammatory action of prednisolone acetate results from its reduction of the permeability of capillaries and vascular proliferation and from the inhibition of the fibroblast action. Membranes of the liposomes are stabilized against hypoxia, toxins and others.

The fast relief from pain and itching as well as the reduction of local oedema and inflammation help in preventing secondary trauma or injuries caused by excessive licking, abrasions, violent head-scratching and bites.

5.2 Pharmacokinetic particulars
Several laboratory experiments have shown that there is almost no systemic absorption through the skin or mucous membranes after topical application of miconazole nitrate and polymyxin B, and the absorption through damaged skin or other injuries is negligible.
The systemic absorption of prednisolone through intact or damaged skin is minimal.

The obstacle to the systemic absorption seems to be localised at the dermo-epidermal junction where it forms long-term deposits on the superficial layers of the epidermis with no significant systemic absorption.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Silica colloidal anhydrous
Paraffin, liquid

6.2 Major ncompatibilities
None known.
Avoid concomitant use with other topical products.

6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: 3 months.

6.4 Special precautions for storage
Do not store above 25 °C.
Store in the original container.

6.5 Nature and composition of immediate packaging
LDPE squeeze dropper bottle of 15 ml or 30 ml with a screw cap.
LDPE bottle of 15 ml or 30 ml with squeeze dropper in thermoplastic elastomer and child resistant screw cap in HDPE.
Lithographed carton boxes together with the package leaflet.
Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER
To be completed nationally

8. MARKETING AUTHORISATION NUMBER(S)
To be completed nationally

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation:
Date of last renewal:

10 DATE OF REVISION OF THE TEXT

PROHIBITION OF SALE, SUPPLY AND/OR USE
Veterinary product subject to veterinary prescription.
Administration under the control or the direct responsibility of a veterinary surgeon.

PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE

Lithographed carton boxes

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

MIPREPOL, oily suspension for dogs and cats (IT)
SUROLAN, oily suspension for dogs and cats (ES, PT)
Miconazole nitrate, Prednisolone acetate, Polymyxin B sulfate

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:

Active substances:
20 mg Miconazole (as nitrate)
4.48 mg Prednisolone (as acetate)
0.5293 mg Polymyxin B sulfate

3. PHARMACEUTICAL FORM

Oily suspension for topical use.

4. PACKAGE SIZE

15 ml
30 ml

5. TARGET SPECIES

Dogs and cats

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

9. SPECIAL WARNING(S), IF NECESSARY

For external use only.

Shake the bottle well before use.

10. EXPIRY DATE

EXP.
Once opened use within3 months.

11. SPECIAL STORAGE CONDITIONS

Do not store above 25 °C.
Store in the original container.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Dispose of waste material in accordance with local requirements.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only.
To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

To be completed nationally

16. MARKETING AUTHORISATION NUMBER(S)

To be completed nationally

17. MANUFACTURER'S BATCH NUMBER

Lot n.

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

15 ml bottle; 30 ml bottle

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

MIPREPOL, oily suspension for dogs and cats (IT)
SUROLAN, oily suspension for dogs and cats (ES, PT)
Miconazole nitrate, Prednisolone acetate, Polymyxin B sulfate

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

Each ml contains:
Active substances:
20 mg Miconazole (as nitrate)
4.48 mg Prednisolone (as acetate)
0.5293 mg Polymyxin B sulfate

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

15 ml
30 ml

4. ROUTE(S) OF ADMINISTRATION

For external use only.

5. WITHDRAWAL PERIOD(S)

6. BATCH NUMBER

Lot n.

7. EXPIRY DATE

EXP.
Once opened use within 3 months.

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

PACKAGE LEAFLET:
MIPREPOL (IT) SUROLAN (ES; PT), oily suspension for dogs and cats

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:
To be completed nationally

Manufacturer responsible for batch release:
Lusomedicamenta, Sociedade Técnica Farmacéutica, SA
Estrada Consiglieri Pedroso, 66, 69-B
Queluz de Baixo
2730-055 Barcarena (Portugal)

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

MIPREPOL (IT) SUROLAN (ES; PT), oily suspension for dogs and cats
Miconazole nitrate, Prednisolone acetate, Polymyxin B sulfate

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each ml contains:
Active substances:
20 mg Miconazole (as nitrate)
4.48 mg Prednisolone (as acetate)
0.5293 mg Polymyxin B sulfate

4. INDICATIONS

Cats and dogs: topical treatment of otitis externa and skin infections caused by the following susceptible species:

Fungi and yeasts
Microsporum spp
Trichophyton spp.
Candida spp.
Malassezia pachydermatis
Gram-positive bacteria
Staphylococcus spp.
Streptococcus spp.
Gram-negative bacteria
Pseudomonas spp.
Escherichia coli

In the case of external otitis due to ear mites (*Otodectes cynotis*), the effect of this product is due to a physical action of its excipient and not to the intrinsic activity of the active substances. Its use in this indication has to be chosen only when there is a secondary infection caused by susceptible organisms.

The product also has anti-inflammatory and anti-pruritic activity.

5. CONTRAINDICATIONS

Do not use in animals with perforated ear drums since Polymixin B is known to be a potential ototoxic agent.
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

6. ADVERSE REACTIONS

In very rare case hypersensitivity or allergic reactions to any of the active substances or excipients may occur.
Long-term use of topical corticosteroids may cause very rare local or systemic effect, including skin thinning and delay wound healing. Their immunosuppressant actions may weaken resistance to or exacerbate existing infections.
In very rare occasions the use of this product may be associated with deafness, mainly in elderly dogs. If this occurs, treatment should be stopped. Decreased hearing or deafness was reversible in the majority of cases.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Dogs and cats

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For topical administration. Shake the bottle well before use.
At the beginning of treatment, hair surrounding or covering the lesions must be clipped; this should be repeated during treatment if necessary.
Ears:
Clean the auditory canal and place 3-5 drops of the product into the ear twice daily.
Massage the ear and the auditory canal gently but thoroughly to ensure proper distribution.
For infections caused *by Otodectes cynotis*, instill five drops twice daily for 14 days.

Skin: Having ensured the area to be treated is clean, apply a few drops of the product (depending on lesion size) twice a day. Wear single use disposable gloves and rub well.

Treatment should be continued until a few days after complete disappearance of the clinical symptoms. In some obstinate cases, treatment may be required for 2 to 3 weeks.

9. ADVICE ON CORRECT ADMINISTRATION

10. WITHDRAWAL PERIOD

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
Do not store above 25°C.
Store in the original container.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.
Shelf life after first opening the container: 3 months.

12. SPECIAL WARNING(S)

This veterinary medicinal product does not contain any antimicrobial preservative.

Special precautions for use in animals:
For external use only.

Whenever possible, the veterinary medicinal product should only be used based on susceptibility testing.
Official, national and local antimicrobial policies should be taken into account when the product is used.
Use of the product deviating from the instructions given in the SPC may increase the prevalence of resistant bacteria, fungi or yeasts to polimixin B or miconazol respectively.

Before the product is applied, the external auditory canal must be examined to ensure that the eardrum is not perforated in order to avoid the risk of transmission of the infection to the middle ear and to prevent damage to the cochlear and vestibular apparatus.
After recovery, ears should be checked at regular intervals for signs of reinfection.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

- In case of accidental contact with eyes, seek medical advice immediately and show the package leaflet or the label to the physician.
- People with known hypersensitivity to the active substances should avoid contact with the veterinary medicinal product.
- Personal protective equipment consisting of single use disposable gloves should be worn when handling the veterinary medicinal product.
- The veterinary medicinal product should not be administered by pregnant women.

Pregnancy and Lactation:
Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:
None known.

Overdose (symptoms, emergency procedures, antidotes):
No data available. Do not exceed the recommended dosage.

Incompatibilities:
None known.
Avoid concomitant use with other topical products.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

15. OTHER INFORMATION

MIPREPOL/SUROLAN is available in 15 ml and 30 ml plastic bottles.
Not all pack sizes may be marketed.